Related Experiment Video
Updated: May 1, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Successes and limitations of targeted cancer therapy in melanoma
Emanuela Romano1, Olivier Michielin
1Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Abstract:
The treatment of stage IV melanoma has witnessed a very impressive pace of innovation in recent years, to a point where the management of these patients has very little in common to what was standard practice 5 years ago. If the gain in overall survival, the high response rates or the induction of a significant fraction of long survivors are all very exciting news for our patients and their families, the path that led to these discoveries is as important. Rather than empirical, the development of these new strategies has been extremely rational, based on state-of-the-art basic biology and immunology, exemplary translational research and, finally, hypothesis-driven targeted trials that led to rapid approval. In this review, we will cover all the new targeted therapies that have emerged as the results of these translational programs, focusing mainly on signaling pathway- and immune checkpoint-targeted therapies. Taken collectively, these new developments set the bar for a new paradigm in future translational and clinical research in both melanoma as well as other tumor types.
Insights
Recent advancements in stage IV melanoma treatment, driven by basic biology and immunology, have revolutionized patient care. New targeted therapies and immune checkpoint inhibitors offer improved survival and response rates, setting a new standard for research.
Area of Science:
- Oncology
- Immunology
- Translational Research
Background:
- Stage IV melanoma treatment has rapidly evolved beyond previous standards of care.
- Recent innovations offer significant gains in overall survival and high response rates.
Purpose of the Study:
- To review novel targeted therapies and immune checkpoint inhibitors for stage IV melanoma.
- To highlight the rational, biology-driven approach in developing these new treatment strategies.
Main Methods:
- Review of recent translational research and clinical trial outcomes.
- Focus on targeted therapies inhibiting key signaling pathways.
- Analysis of immune checkpoint-targeted therapies.
Main Results:
- Significant improvements in overall survival and response rates for stage IV melanoma patients.
- Identification of a fraction of patients achieving long-term survival.
- Emergence of targeted signaling pathway inhibitors and immune checkpoint modulators.
Conclusions:
- New targeted and immune-based therapies represent a paradigm shift in stage IV melanoma management.
- The rational, translational approach is crucial for developing effective cancer treatments.
- These advancements provide a new benchmark for future melanoma and other cancer research.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers